Eli Lilly and QurCan sign genetic medicine deal
Pharmaceutical Business Review·Best Pharmaceutical Stocks To Watch Now - September 15th
Market Beat·- MarketBeat's stock screener tool identified Eli Lilly and Company, Johnson & Johnson, Pfizer, Merck & Co., Inc., and AbbVie as the top five pharmaceutical stocks to watch based on high dollar trading volume. - These companies are engaged in discovering, developing, manufacturing, and selling prescription and over-the-counter drugs across various therapeutic areas such as diabetes, oncology, immunology, and vaccines. - Investments in pharmaceutical stocks offer growth potential driven by successful medicines and strong demand, while carrying risks related to clinical trials, regulatory approvals, patent expirations, and pricing pressures.Eli Lilly Stock (LLY) Gets New Buy Rating as Weight-Loss Drug Sales Accelerate
Tip Ranks·- Brokerage Berenberg upgraded Eli Lilly ( LLY ) to a buy rating and raised its target price to USD 1400. - The upgrade is driven by accelerating sales of weight-loss drugs and robust demand from the Medicare GLP-1 bridging program. - Eli Lilly has committed approximately USD 60 billion across more than 25 business development transactions to strengthen its pipeline.Eli Lilly Stock (LLY) Has 45% Upside, Says Citigroup
Tip Ranks·- Citigroup set a new Wall Street high price target of 1 600 USD for Eli Lilly, projecting a 45% upside potential while reaffirming a buy rating. - The analyst highlighted that Eli Lilly dominates the global weight loss drug market with a 60% market share and robust quarterly sales of 14.9 billion USD. - This bullish outlook coincides with competitor Novo Nordisk rebranding and updating its corporate culture to regain market share in the obesity drug sector.